Concepedia

José Rodrigues Pereira

JR

Statistics

Publications

20

Citations

13.2K

H-Index

19

Active since

1999

Affiliations

Institute of Oncology Prof. Dr. Ion Chiricuta(Current)

Instituto do Câncer do Estado de São Paulo

Universidade de São Paulo

The Maria Sklodowska-Curie National Research Institute of Oncology

Eli Lilly (United States)

José Rodrigues Pereira is an author at Institute of Oncology Prof. Dr. Ion Chiricuta specializing in medicine, lung cancer, and oncology.

Top concepts

Publications per year

1999–2013

20

Publications

20

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

, , +6

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations

, , +10

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

, , +6

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2006 · 702 citations · Full text

1–5 of 20